Bibliography

Research using CPRD data has informed drug safety guidance and clinical practice and resulted in over 2,400 peer-reviewed publications.

The CPRD bibliography is updated on a monthly basis (last updated 5 February 2020) and papers are listed below and in the PDF below.

If you have published papers using CPRD data which are not included in this list, please contact us at enquiries@cprd.com so that we can update the bibliography.

Download: 

(PDF, 3MB, 197 pages)

 

Export 2449 results:
Author Title [ Type(Desc)] Year
Journal Article
B. Yang, Petrick, J. L., Chen, J., Hagberg, K. W., Sahasrabuddhe, V. V., Graubard, B. I., Jick, S., and McGlynn, K. A., “Associations of NSAID and paracetamol use with risk of primary liver cancer in the Clinical Practice Research Datalink”, Cancer Epidemiol, vol. 43, pp. 105-11, 2016.
M. T. Redaniel, Jeffreys, M., May, M. T., Ben-Shlomo, Y., and Martin, R. M., “Associations of type 2 diabetes and diabetes treatment with breast cancer risk and mortality: a population-based cohort study among British women”, Cancer Causes Control, vol. 23, pp. 1785-95, 2012.
S. R. Pye, Sheppard, T., Joseph, R. M., Lunt, M., Girard, N., Haas, J. S., Bates, D. W., Buckeridge, D. L., van Staa, T. P., Tamblyn, R., and Dixon, W. G., “Assumptions made when preparing drug exposure data for analysis have an impact on results: An unreported step in pharmacoepidemiology studies”, Pharmacoepidemiol Drug Saf, vol. 27, pp. 781-788, 2018.
C. Vasilakis-Scaramozza, Aschengrau, A., Cabral, H. J., and Jick, S. S., “Asthma drugs and the risk of congenital anomalies”, Pharmacotherapy, vol. 33, pp. 363-8, 2013.
R. A. Charlton, Hutchison, A., Davis, K. J., and de Vries, C. S., “Asthma management in pregnancy”, PLoS One, vol. 8, p. e60247, 2013.
R. A. Charlton, Pierini, A., Klungsoyr, K., Neville, A. J., Jordan, S., van den Berg, L. T. de Jong, Thayer, D., Bos, H. J., Puccini, A., Hansen, A. V., Gini, R., Engeland, A., Andersen, A. M. Nybo, Dolk, H., and Garne, E., “Asthma medication prescribing before, during and after pregnancy: a study in seven European regions”, BMJ Open, vol. 6, p. e009237, 2016.
K. E. Lowe, Mansfield, K. E., Delmestri, A., Smeeth, L., Roberts, A., Abuabara, K., Prieto-Alhambra, D., and Langan, S. M., “Atopic eczema and fracture risk in adults: A population-based cohort study”, J Allergy Clin Immunol, 2019.
Y. Schonmann, Mansfield, K. E., Hayes, J. F., Abuabara, K., Roberts, A., Smeeth, L., and Langan, S. M., “Atopic eczema in adulthood and risk of depression and anxiety: a population-based cohort study”, J Allergy Clin Immunol Pract, 2019.
A. C. Scowcroft and Cowie, M. R., “Atrial fibrillation: improvement in identification and stroke preventive therapy - data from the UK Clinical Practice Research Datalink, 2000-2012”, Int J Cardiol, vol. 171, pp. 169-73, 2014.
S. McCarthy, Asherson, P., Coghill, D., Hollis, C., Murray, M., Potts, L., Sayal, K., de Soysa, R., Taylor, E., Williams, T., and Wong, I. C., “Attention-deficit hyperactivity disorder: treatment discontinuation in adolescents and young adults”, Br J Psychiatry, vol. 194, pp. 273-7, 2009.
V. Prasad, West, J., Kendrick, D., and Sayal, K., “Attention-deficit/hyperactivity disorder: variation by socioeconomic deprivation”, Arch Dis Child, 2018.
N. N. Mehta, Yu, Y., Pinnelas, R., Krishnamoorthy, P., Shin, D. B., Troxel, A. B., and Gelfand, J. M., “Attributable risk estimate of severe psoriasis on major cardiovascular events”, Am J Med, vol. 124, pp. 775.e1-6, 2011.
L. L. Lipscombe, Austin, P. C., Alessi-Severini, S., Blackburn, D. F., Blais, L., Bresee, L., Filion, K. B., Kawasumi, Y., Kurdyak, P., Platt, R. W., Tamim, H., and Paterson, J. M., “Atypical antipsychotics and hyperglycemic emergencies: multicentre, retrospective cohort study of administrative data”, Schizophr Res, vol. 154, pp. 54-60, 2014.
H. Jick and Kaye, J. A., “Autism and DPT vaccination in the United Kingdom”, N Engl J Med, vol. 350, pp. 2722-3, 2004.
A. Lawson, West, J., Aithal, G. P., and Logan, R. F., “Autoimmune cholestatic liver disease in people with coeliac disease: a population-based study of their association”, Aliment Pharmacol Ther, vol. 21, pp. 401-5, 2005.
T. M. Anssar, Leitzmann, M. F., Linker, R. A., Meier, C., Becker, C., Jick, S., Sahm, K., Platten, M., Hau, P., and Seliger, C., “Autoimmune diseases and immunosuppressive therapy in relation to the risk of glioma”, Cancer Med, 2019.
K. W. Littink, Stappers, P. T. Y., Riemslag, F. C. C., Talsma, H. E., van Genderen, M. M., Cremers, F. P. M., Collin, R. W. J., and van den Born, L. I., “Autosomal Recessive NRL Mutations in Patients with Enhanced S-Cone Syndrome”, Genes (Basel), vol. 9, 2018.
B. A. Dickerman, Garcia-Albeniz, X., Logan, R. W., Denaxas, S., and Hernan, M. A., “Avoidable flaws in observational analyses: an application to statins and cancer”, Nat Med, 2019.
I. J. Douglas, Bhaskaran, K., Batterham, R. L., and Smeeth, L., “Bariatric Surgery in the United Kingdom: A Cohort Study of Weight Loss and Clinical Outcomes in Routine Clinical Care”, PLoS Med, vol. 12, p. e1001925, 2015.
K. van Brunt, Curtis, B., Ivanyi, T., Balogh, E., Chalkiadaki, C., MacLachlan, S., Neasham, D., and Raluy-Callado, M., “Basal-bolus Therapy in Patients with Type 2 Diabetes Mellitus in the UK: Patient Characteristics, Treatment Patterns and the Effect of Switching to Premixed Insulin”, Diabetes Ther, vol. 7, pp. 793-807, 2016.
S. F. Lanes, Rodrigeuz, L. A., and Hwangg, E., “Baseline risk of gastrointestinal disorders among new users of meloxicam, ibuprofen, diclofenac, naproxen and indomethacin”, Pharmacoepidemiol Drug Saf, vol. 9, pp. 113-7, 2000.
J. Stowe, Andrews, N., Wise, L., and Miller, E., “Bell's palsy and parenteral inactivated influenza vaccine”, Hum Vaccin, vol. 2, pp. 110-2, 2006.
J. P. Sheppard, Stevens, S., Stevens, R., Martin, U., Mant, J., Hobbs, F. D. R., and McManus, R. J., “Benefits and Harms of Antihypertensive Treatment in Low-Risk Patients With Mild Hypertension”, JAMA Intern Med, vol. 178, pp. 1626-1634, 2018.
D. B. Wolfson, Best, A. F., Addona, V., Wolfson, J., and Gadalla, S. M., “Benefits of combining prevalent and incident cohorts: An application to myotonic dystrophy”, Stat Methods Med Res, p. 962280218804275, 2018.
R. Alsaggaf, St George, D. M. M., Zhan, M., Pfeiffer, R. M., Wang, Y., Anderson, L. A., Liu, Z., Koshiol, J., Bauer, A. J., Wagner, K. R., Greene, M. H., Amr, S., and Gadalla, S. M., “Benign tumors in myotonic dystrophy type I target disease-related cancer sites”, Ann Clin Transl Neurol, vol. 6, pp. 1510-1518, 2019.
P. Imfeld, Bodmer, M., Jick, S. S., and Meier, C. R., “Benzodiazepine Use and Risk of Developing Alzheimer's Disease or Vascular Dementia: A Case-Control Analysis”, Drug Saf, vol. 38, pp. 909-19, 2015.
A. Palmaro, Dupouy, J., and Lapeyre-Mestre, M., “Benzodiazepines and risk of death: Results from two large cohort studies in France and UK”, Eur Neuropsychopharmacol, vol. 25, pp. 1566-77, 2015.
C. McCourt, Coleman, H. G., Murray, L. J., Cantwell, M. M., Dolan, O., Powe, D. G., and Cardwell, C. R., “Beta-blocker usage after malignant melanoma diagnosis and survival: a population-based nested case-control study”, Br J Dermatol, vol. 170, pp. 930-8, 2014.
C. R. Cardwell, Coleman, H. G., Murray, L. J., Entschladen, F., and Powe, D. G., “Beta-blocker usage and breast cancer survival: a nested case-control study within a UK clinical practice research datalink cohort”, Int J Epidemiol, vol. 42, pp. 1852-61, 2013.
B. M. Hicks, Murray, L. J., Powe, D. G., Hughes, C. M., and Cardwell, C. R., “beta-Blocker usage and colorectal cancer mortality: a nested case-control study in the UK Clinical Practice Research Datalink cohort”, Ann Oncol, vol. 24, pp. 3100-6, 2013.
C. Renoux, Dell'Aniello, S., Brenner, B., and Suissa, S., “Bias from depletion of susceptibles: the example of hormone replacement therapy and the risk of venous thromboembolism”, Pharmacoepidemiol Drug Saf, vol. 26, pp. 554-560, 2017.
S. J. Sinnott, Mansfield, K. E., Schmidt, M., Bhaskaran, K., Smeeth, L., Nitsch, D., and Tomlinson, L. A., “Biochemical monitoring after initiation of aldosterone antagonist therapy in users of renin-angiotensin system blockers: a UK primary care cohort study”, BMJ Open, vol. 7, p. e018153, 2017.
J. Spoendlin, Meier, C., Jick, S. S., and Meier, C. R., “Bisphosphonate therapy start may transiently increase the risk of tendon rupture in patients with glucocorticoid co-medication: a population-based observational study”, Pharmacoepidemiol Drug Saf, vol. 25, pp. 1116-1123, 2016.
W. G. Dixon and Solomon, D. H., “Bisphosphonates and esophageal cancer–a pathway through the confusion”, Nat Rev Rheumatol, vol. 7, pp. 369-72, 2011.
E. Wright, Schofield, P. T., Seed, P., and Molokhia, M., “Bisphosphonates and risk of upper gastrointestinal cancer–a case control study using the General Practice Research Database (GPRD)”, PLoS One, vol. 7, p. e47616, 2012.
C. Ang, Doyle, E., and Branch, A., “Bisphosphonates as potential adjuvants for patients with cancers of the digestive system”, World J Gastroenterol, vol. 22, pp. 906-16, 2016.
K. Donegan, Beau-Lejdstrom, R., King, B., Seabroke, S., Thomson, A., and Bryan, P., “Bivalent human papillomavirus vaccine and the risk of fatigue syndromes in girls in the UK”, Vaccine, vol. 31, pp. 4961-7, 2013.
N. Ismail, Jordan, K. P., Kadam, U. T., Edwards, J. J., Kinnaird, T., and Mamas, M. A., “Bleeding After Hospital Discharge Following Acute Coronary Syndrome: Incidence, Types, Timing, and Predictors”, J Am Heart Assoc, vol. 8, p. e013679, 2019.
O. A. Oshagbemi, Franssen, F. M. E., van Kraaij, S., Braeken, D. C. W., Wouters, E. F. M., van der Zee, A. H. Maitlan, Driessen, J. H. M., and de Vries, F., “Blood Eosinophil Counts, Withdrawal of Inhaled Corticosteroids and Risk of COPD Exacerbations and Mortality in the Clinical Practice Research Datalink (CPRD)”, Copd, pp. 1-8, 2019.
O. A. Oshagbemi, Franssen, F. M. E., Braeken, D. C. W., Henskens, Y., Wouters, E. F. M., van der Zee, A. H. Maitlan, Burden, A. M., and de Vries, F., “Blood eosinophilia, use of inhaled corticosteroids, and risk of COPD exacerbations and mortality”, Pharmacoepidemiol Drug Saf, vol. 27, pp. 1191-1199, 2018.
C. A. Emdin, Rothwell, P. M., Salimi-Khorshidi, G., Kiran, A., Conrad, N., Callender, T., Mehta, Z., Pendlebury, S. T., Anderson, S. G., Mohseni, H., Woodward, M., and Rahimi, K., “Blood Pressure and Risk of Vascular Dementia: Evidence From a Primary Care Registry and a Cohort Study of Transient Ischemic Attack and Stroke”, Stroke, vol. 47, pp. 1429-35, 2016.
J. Delgado, Bowman, K., Ble, A., Masoli, J., Han, Y., Henley, W., Welsh, S., Kuchel, G. A., Ferrucci, L., and Melzer, D., “Blood Pressure Trajectories in the 20 Years Before Death”, JAMA Intern Med, vol. 178, pp. 93-99, 2018.
N. Qizilbash, Gregson, J., Johnson, M. E., Pearce, N., Douglas, I., Wing, K., Evans, S. J. W., and Pocock, S. J., “BMI and risk of dementia in two million people over two decades: a retrospective cohort study”, Lancet Diabetes Endocrinol, vol. 3, pp. 431-436, 2015.
H. Strongman, Brown, A., Smeeth, L., and Bhaskaran, K., “Body mass index and Hodgkin's lymphoma: UK population-based cohort study of 5.8 million individuals”, Br J Cancer, 2019.
W. A. Blumentals, Nevitt, A., Peng, M. M., and Toovey, S., “Body mass index and the incidence of influenza-associated pneumonia in a UK primary care cohort”, Influenza Other Respir Viruses, vol. 6, pp. 28-36, 2012.
S. Kent, Jebb, S. A., Gray, A., Green, J., Reeves, G., Beral, V., Mihaylova, B., and Cairns, B. J., “Body mass index and use and costs of primary care services among women aged 55-79 years in England: a cohort and linked data study”, Int J Obes (Lond), 2018.
K. Bhaskaran, Douglas, I., Forbes, H., dos-Santos-Silva, I., Leon, D. A., and Smeeth, L., “Body-mass index and risk of 22 specific cancers: a population-based cohort study of 5.24 million UK adults”, Lancet, vol. 384, pp. 755-65, 2014.
W. G. Herrington, Smith, M., Bankhead, C., Matsushita, K., Stevens, S., Holt, T., Hobbs, F. D., Coresh, J., and Woodward, M., “Body-mass index and risk of advanced chronic kidney disease: Prospective analyses from a primary care cohort of 1.4 million adults in England”, PLoS One, vol. 12, p. e0173515, 2017.
J. H. Driessen, Henry, R. M., van Onzenoort, H. A., Lalmohamed, A., Burden, A. M., Prieto-Alhambra, D., Neef, C., Leufkens, H. G., and de Vries, F., “Bone fracture risk is not associated with the use of glucagon-like peptide-1 receptor agonists: a population-based cohort analysis”, Calcif Tissue Int, vol. 97, pp. 104-12, 2015.
R. I. Furlano, Bloechliger, M., Jick, H., and Meier, C. R., “Bone fractures in children with autistic spectrum disorder”, J Dev Behav Pediatr, vol. 35, pp. 353-9, 2014.
[Page last reviewed 5 February 2020]